
USD
+$0.00
(+0.00%
)At Close (As of Dec 9, 2025)
$142.03M
Market Cap
-
P/E Ratio
-2.22
EPS
$4.98
52 Week High
$1.15
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$1.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$141M |
| Selling General And Administrative | $72M |
| Research And Development | $70M |
| Operating Expenses | $141M |
| Investment Income Net | - |
| Net Interest Income | $8.5M |
| Interest Income | $8.5M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1M |
| Income Before Tax | -$24M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$142M |
| Ebitda | -$141M |
| Net Income | -$24M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$1.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$141M |
| Selling General And Administrative | $72M |
| Research And Development | $70M |
| Operating Expenses | $141M |
| Investment Income Net | - |
| Net Interest Income | $8.5M |
| Interest Income | $8.5M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1M |
| Income Before Tax | -$24M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$142M |
| Ebitda | -$141M |
| Net Income | -$24M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Cassava Sciences, Inc. is a clinical-stage biotechnology firm headquartered in Austin, Texas, focused on developing breakthrough therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its leading candidate, simufilam, is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. By targeting significant unmet medical needs in neurology, Cassava aims to revolutionize the treatment paradigm for neurodegenerative disorders, setting a foundation for improving patient outcomes and quality of life while enhancing its strategic position within the biotechnology sector.